|
|
|
Gastroenterologie und Ernährung Die Forschungsaktivitäten konzentrieren sich auf die Erforschung der Pathogenese allergischer Darmerkrankungen (Frau Univ. Prof. Dr. Almuth Christine Hauer).
Weitere Forschungsschwerpunkte beziehen
sich auf epidemiologische Fragestellungen zur Zöliakie, Erweiterung
neuer multidisziplinärer Diagnostik und Therapie bei funktionellen
Störungen des Magen-Darmtrakts (zB Säuglingskoliken) sowie
epidemiologische, diagnostische und therapeutische Probleme in der
Hepatologie. |
|
Hauer, A.Ch., Breese E., Walker-Smith J.A., MacDonald T.T.: The frequency of cells secreting Interferon-g, Interleukin-4, Interleukin-5 and Interleukin-10 in the blood and duodenal mucosa of children with cow’s milk hypersensitivity.
Pediatr
Res 1997, 42 (5):629-38 Hauer, A.Ch., Finn T., MacDonald T.T., Spencer J., Isaacson P.: Analysis of TH1 and TH2 cytokine production in low grade B cell gastric MALT-type lymphomas stimulated in vitro with Helicobacter pylori
J Clin
Pathol 1997, 50 (11):957-59 Hauer, A. Ch., Bajaj-Elliott M., Williams Ch. B., Walker-Smith JA., MacDonald TT.: An Analysis of Interferon-g, IL-4, IL-5 and IL-10 Production by Elispot and quantitative reverse transcriptase-PCR in Human Peyer’s Patches
Cytokine 1998, Vol.
10, No.8, p. 627-634 Hauer, A.Ch., Griessl, A., Riederer, M., MacDonald TT.: T Helper 2 (TH2) cytokines in the response of newborn human infants to cow’s milk proteins
J
Paediatr Gastroenterol Nutr 1998, Vol. 26, No. 5, p. 548 Hauer, A.Ch., Griessl, A., Riederer M., MacDonald TT.: Spontaneous and cow’s milk protein (CMP)-induced secretion of T-helper 2 (Th2) cytokines in perterm and term infants
Immunol
letters 1999, 69 (1): 102 Hauer A.Ch., Riederer M., Griessl A., Rosegger H., MacDonald T.T.: Cytokine production by cord blood mononuclear cells stimulated with cows milk proteins in vitro: interleukin-4 and transforming growth factor b-secreting cells detected in the CD45R0 T cell population in children of atopic mothers
Clin Exp Allergy
2003, 33:615-623 Hauer, A.Ch., Hoekstra J.H., Sandhu B., Szajewska H.: Behandlung der akuten Gastroenteritis in Österreich im europaweiten Vergleich: Ergebnisse im Rahmen einer multizentrischen Studie der ESPGHAN
Monatsschr
Kinderheilkunde 2003; 151 (5):532-538 Hauer, A.Ch., Deutsch J., Goriup U., Eherer A., Weber-Mzell D., et al. Serologisches Screening zur Prävalenzermittlung der Zöliakie in Österreich
Acta Medica Austriaca
2003 (Jahrgang 30), Sonderheft 1, S. 10-11 Weber-Mzell, D., Kotanko P., Hauer AC., et al.: Gender, age and seasonal effects on IgA deficiency: a study in 7293 Caucasians
European J of Clin Investigation 2004; 34(3):224-228 Weber-Mzell, D., Hauer AC., et al.: Screening of healthy schoolchildren aged 6-17 years old for immunoglobulin A deficiency in eastern Turkey: authors’ reply. Letter to the Editor
European J of Clin Investigation 2004; 34(10):717 Weber-Mzell, D., Kotanko P., Hauer AC., et al.: Gender, age and seasonal effects on IgA deficiency in Caucasians
J of
Paediatr Gastroenterol Nutr 2004; 39 (suppl 1): S213 Hauer AC, Deutschmann A., Lanner N., Deutsch J. “Case finding” statt Populationsscreening – verbesserte Ermittlung von Zöliakiepatienten?
Z
Gastroenterol 2005; 43:538 Weber-Mzell, Hauer AC., et al. Genetic predisposition for primary hypolactasia of the adult type in children and adolescents with recurrent abdominal pain (RAP) J Paediatr Gastroenterol Nutr 2005 (5):PN2-22, 63
|
|
Hämostaseologie und Hämophilie Ziel der
pädiatrisch hämostasischen Forschung ist
es, durch Verbesserung der wissenschaftlichen Grundlagen zum
Fortschritt in Diagnostik und Therapie von Hämostasestörungen
(Störungen der Blutstillung) im Kindesalter beizutragen:
Insbesondere im Hämostasesystem von Neugeborenen und jungen Kindern
bestehen eine Reihe von Unterschieden im Vergleich zum späteren
Lebensalter. Auch die Prävalenz und das Erscheinungsbild erworbener
Gerinnungsstörungen unterscheidet sich von denen im späteren
Lebensalter. Diagnostik und Therapie angeborener Hämostasestörungen
betreffen vor allem das Kinder- und Jugendlichenalter. |
| Publikationen von 1998 bis 2005 |
|
Zenz W., Bodo Z., Plotho J., Streiff W.,
Male Ch., Bernert G., Rauter L., Gebetsberger G., Kaltenbrunner K.,
Kurnik P., Lischka A., Paky F., Ploier R., Höfler G., Mannhalter
Ch., Muntean W.: „Faktor V Leiden and prothrombin gene G 20210 A variant in children with ichemic stroke“ Tromb Haemost. 1998; 80: 763-66. IF: 4,983 |
|
Gallistl S., Mangge H., Neuwirth G.,
Muntean W.: “Activation of the haemostatic system in children with juvenile rheumatoid arthritis correlates with disease activity“ Throbos Res.1998; 92: 267-72.IF: 1,153 |
|
Gallistl S., Reitinger T., Linhart W.,
Muntean W.: “Thr role of inherited thrombotic disorders in the etiology of Legg-Calve-Perthes disease“ Pediatr Orthopaed. 1998; 19: 82-83.IF: 0,56 |
|
Muntean W.: „Coagulation and anticoagulation in extracorporeal membrane oxygenation“ Artif. Organs, 1999; 23: 979-83. IF: 0,854 |
|
Gallistl S., G. Cvirn, W. Muntean: „Recombinant factor VIIa does not induce hypercoagulability in vitro“ Thromb Haemost. 1999; 81: 245-49. IF: 4,983 |
|
G. Cvirn, S. Gallistl, W. Muntean: „Effects of antithrombin III and protein C on thrombin generation in newborn and adult plasma“ Thromb Res. 1999; 93: 183-90. IF: 1,207 |
|
Raith W., Fauler G., Pichler G., Muntean
W.: "Plasma concentration after intravenous administration of phylloquinone (vitamin K1) in preterm and sick neonates" Thromb Res. 2000; 99: 467-72. IF:1,323 |
|
Giradi L., Sudi K., Muntean W.: "Effect of heparin, platelets, activated platelets, platelet fragments, and hematocrit on activated clotting time" Artif Organs. 2000; 24: 507-13.IF: 0,982 |
|
Gallistl S., Sudi K., Mangge H., Erwa
W., Borkenstein M.: "Insulin is an independent correlate of plasma homocysteine levels in obese children and adolescents" Diabetes Care. 2000; 23: 1348-52. IF: 4,992 |
|
Köstenberger M., Gallistl S., Cvirn G.,
Roschitz B., Muntean W.: "Effects of the glycoprotein IIb/IIIa receptor antagonist c7E3 Fab and anticoagulants on platelet aggregation and thrombin potential under high coagulant challenge in vitro" Blood Coagul Fibrinolysis. 2000; 11: 425-32.IF:1,938 |
|
Sudi K., Gallistl S., Weinhandl G.,
Muntean W., Borkenstein M.: "Relationship between plasminogen acitvator inhibitor-1 antigen, leptin, and fat mass in obese children and adolescents" Metabolism. 2000; 49: 890-95. IF:1,952 |
|
Sudi K. Gallistl S., Tafeit E., Möller
R., Borkenstein M.: "The relationship between different subcutaneous adipose tissue layers, fat mass and leptin in obese children and adolescents" J Pediatr Endocr Met. 2000; 13: 505-12.IF:0,638 |
|
Sudi K., Gallistl S., Weinhandl G.,
Troebinger M., Cartellieri M., Reiterer E., Borkenstein M.: "No evidence for leptin as an independent associate of blood pressure in childhood and juvenile obesity" J Pediatr Endocr Met. 2000; 13: 513-21. IF:0,638 |
|
Köstenberger M., Raith W., Muntean W.: "High titre inhibitor after continuous factor VIII administration for surgery in a young infant" Haemophilia. 2000; 6: 120 (letter). IF:1,408 |
|
Sudi K., Tafeit E., Möller R., Reuterer
E., Gallistl S., Borkenstein M.: "The relationship between differnt subcutaneous adipose tissue layers, fat mass, and leptin in response to short term energy restriction in obese girls" Am J Hum Biol. 2000; 12: 803-13. IF: 0,695 |
|
Sudi K., Gallistl S., Weinhandl G.,
Payer C., Cartellieri M., Borkenstein M.: "No relationship between leptin and cortisol in obese children and adolescents" J Pediatr Endocr Met. 2000; 13: 913-21. IF: 0,635 |
|
Sudi K., Gallistl S., Troebinger M.,
Reiterer E., Payerl D., Aigner R., Borkenstein M.: "Insulin and insulin resistance index are not independent determinants for the variation in leptin in obese children and adolescents" J Pediatr Endocr Met. 2000; 13 : 923-32. IF: 0,638 |
|
Zotter H., Zenz W., Gallistl S., Zöhrer
B., Lindbichler F.: "Stroke following appendectomy under general anesthesia in a patient with basilar impression" Acta Anaesth Scand. 2000; 44: 1271-72. IF: 1,073 |
|
Gallistl S., Sudi K., Borkenstein M.,
Weinhandl G., Muntean W.: "Correlation between cholesterol, soluble P-selectin, and D-dimer in obese children and adolescents" Blood Coagul Fibrinolysis. 2000; 11: 755-61. IF: 1,938 |
|
Dodojacek R., Höfler G., Leschnik B.,
Muntean W.: "A novel type of mutation at the propeptide cleavage site (Ala+1Thr) causing symptomatic protein C type II deficiency" Thromb Res. 2000; 100: 109-13. IF: 1,323 |
|
Gallistl S., Sudi K., Borkenstein M.,
Troebinger M., Weinhandl G., Muntean W.: "Determinants of haemostatic risk factors for coronary heart disease in obese children and adolescents" Int J Obes. 2000; 24: 1459-64. IF: 2,982 |
|
Gallistl S., Sudi k., Leschnik B.,
Muntean W., Borkenstein M.: "Inverse correlation between thyroid function and hemostatic markers for coronary heart disease in obese children and adolescents" J Ped Endocr Met. 2000; 13: 1615-20. IF: 0,638 |
|
Sudi K., Gallistl S., Troebinger M.,
Payerl D., Weinhandl G., Muntean W., Aigner R., Borkenstein M.: "The influence of weight loss on fibrinolytic and metabolic parameters in obese children and adolescents" J Ped Endocr Met. 2001; 14: 85-94. IF: 0,604 |
|
Cvirn G., Gallistl S., Muntean W.: "Alpha-2-Macroglobulin Inhibits the Anticoagulant Action of Activated Protein C in Cord and Adult Plasma" Haemostasis. 2001; 31: 1-11. IF: 1,101 |
|
Muntean W., Gallistl S.: "Antiphospholipid antibodies in children" Thromb Res. 2001; 101: 213-14 (letter). |
|
Cvirn G., S Gallistl., W Muntean: "Effects of alpha 2- macroglobulin and antithrombin on thrombin generation and inhibition in cord and adult plasma" Thromb Res. 2001; 101: 183-91. IF: 1,323 |
|
Gallistl S., Sudi KM., Cvirn G., Muntean
W., Borkenstein M.: "Effekts of short-term energy restriction and physical training on haemostatic risk factors for coronary heart disease in obese children and adolescents" Int J Obest. 2001; 25: 529-32. IF: 2,982 |
|
Sudi KM., Gallistl S., Payerl D., Aigner
R., Möller R., Tafeit E., Borkenstein M.: "Interrelationship between estimates of adiposity and body fat distribution with metabolic and hemostatic parameters in obese children" Metabolism. 2001; 50: 681-87. IF: 1.952 |
|
Roschitz B., Sudi K., Köstenberger M.,
Muntean W.: "Shorter PFA-100® closure times in neonates than in adults: role of red cells, white cells, platelets and von Willebrand factor" Acta Paediatr. 2001; 90: 664-70. IF: 1,315 |
|
Zöhrer B., Zenz W., Rettenbacher A.,
Covi P., Kurnik K., Knoll H., Grubbauer HM., Muntean W.: "Danaparoid sodium (Orgaran®) in four children with heparin-induced thrombocytopenia type II" Acta Paediatr 2001; 90: 765-71. IF: 1,315 |
|
Gallist S., Sudi K., Erwa W., Aigner R.,
Borkenstein M.: "Determinatnts of homocysteine during weight reduction in obese children adolescents" Metabolism. 2001; 50: 1220-23. IF: 1,952 |
|
Sudi K., Gallistl S., Borkenstein M.,
Payerl D., Aigner R., Moller R., Tafeit E.: "Effects of weigth loss on hormones, and measures of adiposity obese children" Endocrine. 2001; 14: 429-35. IF: 1,609 |
|
Sudi KM., Gallistl S., Trobinger M.,
Payerl D., Aigner R., Borkenstein M.: "The effects of changes in body mass and subcutaneous fat on the improvement in metabolic risk factors in obese children after short-term weight loss" Metabolism. 2001 Nov; 50(11):1323-29. IF: 1,952 |
|
Gallistl S., Sudi KM., Aigner R.,
Borkenstein M.: "Changes in serum interleukin-6 concentrations in obese children and adolescents during a weight reduction program" Int J Obest 2001; 25: 1640-43. IF: 2,982 |
|
Gallistl S. "Ausgesuchte Gerinnungsprobleme beim Neugeborenen" Wien. Med. Wschr. 2002; 152:1/2:23-26. |
|
Cvirn G., Gallistl S., Köstenberger M.,
Kutschera J., Leschnik B., Muntean W.: "Alpha 2-macroglobulin level regulates the anticoagulant cofactor activity of protein S in cord and adult plasma" Thromb Res. 2002; 105: 433-39. IF 1,323 |
|
Gallistl S., Cvirn G., Leschnik B.,
Muntean W.: "Respective roles of factors II, VII, IX and X in the procoagulant activity of FEIBA" Blood Coagul Fibrin. 2002; 13: 653-55. IF 1,938 |
|
M. Köstenberger, S. Gallistl, G. Cvirn,
Martina Petritsch, W. Muntean: "Combined effects of eptifibatide and anticoagulants on platelet aggregation and thrombin generation under high and low coagulant challenge" Thromb Haemostasis. 2002; 88: 1012-19. IF 4,910 |
|
W. Muntean: "Fresh frozen plasma in the pediatric age group and in congenital coagulation factor deficiency" Thromb Res. 2002; 107: 29-32. IF 1,446 |
|
P. Hellstern, W. Muntean; W. Schramm, E.
Seifried, BG. Solheim: "Practical guidelines for the clinical use of plasma" Thromb Res. 2002; 107: 53-57. IF 1,446 |
|
Muntean W., Zenz W., Falger J., Male
Ch., Streif W., Wank H., Schwarz R., Kurnik P., Zwieauer K.: "Sixteen Years of Treatment with Pasteurized Human Clotting Factor Concentrates in Children and Adolescents: A Pharmacosurveillance Investigation Comprising 727 Patient Years" Seminars in Thrombosis and Hemostasis. 2002; volume 28, supp, 63-73. IF 2,179 |
|
Cvirn G., Gallistl S., Leschnik Bettina,
Muntean W.: "Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates" J Thromb Haemost. 2003; 1: 263-68. IF 4,831 |
|
Köstenberger M., Muntean W. „Hämophilie. Aktueller Stand von Diagnostik und Therapie“ Pädiat. Prax. 2003; 63: 409-18. |
|
Cvirn G., Gallistl S., Rehak T., Jürgens
G., Muntean W.: “Elevated thrombin-forming capacity of tissue factor-activated cord compared with adult plasma“ J Thromb Haemost. 2003; 1: 1785-90. IF 4,831 |
|
Roschitz B., Beitzke A., Gamillscheg A.,
Sudi K., G. Köstenberger M. Leschnik B., Muntean W.: “Signs of thrombin generation in pediatric cardiac catheterisation with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover“ Thromb Res. 2003; 111: 335-41. IF 1,494 |
|
Zotter
H., Kerbl R., Gallistl S., Nitsche Hilde Borkenstein M.: ”Rewarming Index of the lower leg assessed bys infrared thermography in adolescents with type 1 diabetes mellidus” J Pediatr Endocrinol Metab. 2003 Dec;16(9):1257-62. IF 1,146 |
|
Köstenberger M., Gallistl S., Cvirn G.,
Roschitz Birgit, Rehak Th., Leschnik Bettina, Muntean W.: “Combined effects of melagatran and eptifibatide on platelet aggregation inhibition but not thrombin generation inhibition“ Blood Coagul Fibrinolysis. 2004; 15: 131-37. IF: 1,319 |
|
Köstenberger M., Gallistl S., Cvirn G.,
Muntean W.: ”A laboratory method for parallel determination of platelet aggregation and thrombin generation” Clin Lab. 2004; 50: 41-48. IF: 1,099 |
|
Cvirn G., Gallistl S., Köstenberger M.,
Baier Katrin, Fritsch P., Greilberger J., Jürgens G., Muntean W.:
”The anticoagulant action of recombinant human activated protein C (rhAPC, Drotrecogin α activated): comparison between cord and adult plasma” Thromb Haemost 2004; 91: 912-18. IF: 4,950 |
|
Rehak Th., Cvirn G., Gallistl S.,
Leschnik Bettina, Köstenberger M., Katzer Helga, Ribitsch V.,
Muntean W.: “Increased shear stress- and ristocetin- induced binding of von Willebrand factor to platelets in cord compared with adult plasma“ Thromb Haemost 2004; 92: 678-681. IF: 4,950 |
|
Muntean W., Leschnik Bettina, Baier
Katrin, Cvirn G., Gallistl S.: ”In vivo thrombin generation in neonates” J Thromb Haemost 2004; 2: 2071-2072 (letter). |
|
Köstenberger M., Leschnik Bettina
Muntean W.: ”More on: mild hemophilia A and inhibitor development” J Thromb Haemost. 2004; 2: 676 (letter). |
|
Köstenberger M., Cvirn G., Gallistl S.,
Muntean W.: “Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothromin time and activated partial thromboplastin time” Blood Coagul Fibrinolysis. 2004; 15: 693-97.IF 1,588 |
|
Köstenberger M., Cvirn G., Gallistl S.,
Baier Katrin, Leschnik Bettina, Muntean W.: ”Drotrecogin alfa (activated, Xigris ®) in combination with heparin or melagatran: an in vitro inveataigation” J Thromb Thrombolysis. 2004; 18: 5-10. IF 1,066 |
|
Köstenberger M., Gallistl S., Cvirn G.,
Baier Katrin, Leschnik Bettina, Muntean W.: “Anicoagulant action of melagatran, the actove form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.” Thromb Res. 2005; 115: 135-42. IF 1,710 |
|
Cvirn
Gerhard „The role of inhibitors in hemostasis: A comparison between neonates and adults“ Vascular Disease Prevention 2004; 1: 225-231. |
|
Zotter
H., Gallistl S., Kerbl R., Sauseng W., Borkenstein M.: “Effects of TRH administaration on plasma levels in infants, children and adolescents” J Pediatr Endocrinol Metab. 2004; 17: 1001-06. IF 0,947 |
|
Baier Katrin, Cvirn G., Gallistl S.,
Fritsch P., Leschnik B. Muntean W.: “Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor – activated cord plasma than in adult plasma.“ Pediatr Re. 2005; 57: 685-89. IF 3,064 |
|
Köstenberger M., „Recombinant human activated protein C, heparin, and melagatran in umbilical-cord vs adult plasma.“ Acta Pediatrica. 2005; in press IF 1,128 |
|
Vakzinologie und Spezielle Infektionskrankheiten Schwerpunkte der Forschungsarbeit der Arbeitsgruppe Infektiologie sind Schutzimpfungen, Meningokokkeninfektionen, Neuroborreliosen und FSME-Infektionen. Sowohl im Bereich der Schutzimpfungen als auch bei Meningokokeninfektionen wird durch unsere Arbeitsgruppe jeweils eine große mulitzentrische Studie geleitet. Durch eine internationale Kooperation mit Kollegen aus England, Holland und Frankreich planen wir eine Studie zur Erforschung genetischer Gründe für das Erwerben und das Auftreten verschiedener Verlaufsformen von Meningokokkenerkrankungen bei über 2000 Kindern durchzuführen. Unseres Wissens nach handelt es sich hierbei um das größte Projekt, dass es bisher zur Erforschung dieser Erkrankung gegeben hat. Publikationen:
Zenz
W., B. Zöhrer,
M. Levin, S. Fanconi, T. Hatzis, G. Knight, M. Müllner, S. Faust:
Geishofer
G., A. Binder, M. Müller, B. Zöhrer, B.
Resch, W. Müller, J. Faber, A. Finn, G. Endler, Ch.
Mannhalter, W. Zenz:
Zenz
W., H. Pansi, B. Zöhrer,
I. Mutz, H. Holzmann, A. Kraigher, A. Berghold, D. Spork:
|
|
|
